239 related articles for article (PubMed ID: 7763034)
1. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
3. A new tumor marker MCA in breast cancer diagnosis.
Eskelinen M; Tikanoja S; Collan Y
Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of mucinous-like cancer antigen (MCA) in women with breast disease: preliminary results.
Valenti G; Zanardi S; Valtolina M; Bombardieri E; Boccardo F
Cancer Detect Prev; 1991; 15(4):285-9. PubMed ID: 1794135
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
Cappellari A; Bagarella M; Corradi G
Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
[TBL] [Abstract][Full Text] [Related]
6. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer.
Pirolo F; Pacini P; Borsotti M; la Morgia R; Mungai R; Cappellini M; Cardona G; Cataliotti L; Marzano S; Neri B
Anticancer Res; 1991; 11(2):729-31. PubMed ID: 2064326
[TBL] [Abstract][Full Text] [Related]
7. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining of human breast cancer with a new tumour marker MCA: relation to axillary lymph node involvement, metastasis, and survival.
Eskelinen M; Lipponen P; Collan Y
Anticancer Res; 1990; 10(3):591-6. PubMed ID: 1695077
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
10. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
[TBL] [Abstract][Full Text] [Related]
14. [Carcinoembryonic antigen (CEA) and mucinous-like tumor associated antigen (MAC). Statistic correlation in advanced breast carcinoma].
Sbalzarini G; D'Agostino F; Mercantini F; Girami M; Labadini A; Pandolfi C
Minerva Med; 1991 Dec; 82(12):811-3. PubMed ID: 1780086
[TBL] [Abstract][Full Text] [Related]
15. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
17. Selective or routine axillary disease staging for patients with clinically lymph node-negative breast cancer?
Hieken TJ; Velasco JM
Surgery; 2006 Oct; 140(4):500-7; discussion 507-8. PubMed ID: 17011896
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
[TBL] [Abstract][Full Text] [Related]
19. [Serum concentrations of the MCA tumor marker during pregnancy].
Pütz I; Lang G; Winkler M; Rath W
Zentralbl Gynakol; 1996; 118(7):409-11. PubMed ID: 8766103
[TBL] [Abstract][Full Text] [Related]
20. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
